In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.
Santhera Pharmaceuticals AGis making the bold move of outlicensing to Chiesi Farmaceutici SPA its only revenue generator – Raxone for Leber’s hereditary optic neuropathy (LHON) – to raise funds for the Swiss company's pipeline.
The privately owned Italian group is paying CHF50m ($50m) upfront and near- to mid-term sales milestone payments of up to...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
